Linksbridge

At the International AIDS Society's conference this week, Gilead saw a standing ovation for full Phase 3 data on its 100% efficacious twice-yearly HIV prevention shot. Yet advocates including Médecins Sans Frontières (MSF) and UNAIDS pressed the company to expand global access to lenacapavir by making it available to the Medicines Patent Pool, among other measures:

Join Outright International next week for the launch of the GLIDE landscape analysis—a global view of LGBTQI+ political participation. The Linksbridge Foundation is proud to invest in the work of this inspiring organization.

In this week's newsletter: CEPI (Coalition for Epidemic Preparedness Innovations) and the E.U. have upped their investment in Valneva's chikungunya vaccine; Merck’s prophylactic RSV monoclonal antibody for infants met primary endpoints in a Phase 2b/3 trial; and more.

In this week's newsletter: India rejects J&J’s patent application for a pediatric formulation of TB drug bedaquiline, thanks to a Médecins Sans Frontières (MSF)-backed effort; Drugs for Neglected Diseases initiative - DNDi shares exciting leishmaniasis treatment news; and more.

Linksbridge is hiring! If you have market dynamics experience in global health and/or enjoy problem-solving, please consider applying! Please reach out if you have questions! https://lnkd.in/gNEfPsUZ

The Campaign Hub is a global public good from the Health Campaign Effectiveness Coalition and its partners. By providing unprecedented visibility into campaign-based health delivery around the world, the Campaign Hub improves collaboration among stakeholders at all levels. The result: more effective campaigns delivering better outcomes for human health. In a new report, Linksbridge and coalition partners offer a midyear snapshot of the state of health campaigns, drawing on data from the Campaign Hub: https://lnkd.in/g2ajXF8c

Improving vaccine supply resilience at regional levels requires insights into market health. That's why Linksbridge has supported Gavi and UNICEF in developing a new vaccine market dashboard. Compiling Gavi's market analysis, UNICEF procurement information, and forecasts from the Linksbridge-curated Global Vaccine Market Model, this publicly available tool enhances transparency and expands access to market information. The dashboard is now live on Gavi's website: https://lnkd.in/gsyThVkD

Linksbridge is proud to support the kickoff of the Health Campaign Effectiveness Coalition’s Collaborative Action Strategy in Nigeria! Several of our team members recently traveled to Abuja to introduce Linksbridge's cross-program campaign mapping tool, which can help improve campaign coordination, planning, and integration.   Building on our six years of experience managing the Campaign Hub database and our team's expertise in database infrastructure and data platforms, we hope to continue supporting Nigeria and other countries aiming to increase health campaign effectiveness.   We are excited to learn from our Nigerian colleagues' experiences as they embark on their bold new health campaign journey! See the Campaign Hub here: https://lnkd.in/gX3CrWf9

In a move global health stakeholders are calling “devastating,” Médecins Sans Frontières (MSF) plans to restructure its operations, phasing out the Access Campaign that has helped secure price reductions for treatments for hepatitis C, HIV and TB, among other victories. The campaign’s functions will be rolled into a new unit known as Access to Products for Healthcare, with a focus on “access to specific products needed by MSF’s humanitarian efforts,” according to Health Policy Watch. Former Access Campaign head Tido von Schoen-Angerer told Health Policy Watch that the change was driven by a faction hoping to depoliticize the organization and “no longer willing to take up the political battle.” This week's issue of Linksbridge Pharma has more on MSF, plus HIV PrEP, Africa-based vaccine manufacturing, and other news important to global health. Read it here: https://lnkd.in/gQgqTDD4

Can a rapid antimicrobial susceptibility test for UTIs really open up the possibility of previously 'retired' first-line antibiotics returning to use? After 10 years and more than 250 submissions, U.K.-based Challenge Works has awarded the $10.2 million Longitude Prize on AMR to Sysmex Astrego’s PA-100 AST System, a rapid antimicrobial susceptibility test for urinary tract infections. Announcing the award last week, the subsidiary of U.K. innovation agency Nesta said the point-of-care test can diagnose a bacterial infection in 15 minutes and determine the right antibiotic treatment in 45 minutes—opening up the “significant possibility of previously ‘retired’ first-line antibiotics coming back into use.” Today's new issue of Linksbridge Pharma covers antimicrobial resistance, blood-stage malaria vaccines, self-injectable contraceptives for women in LMICs, and more. Read it here: https://lnkd.in/gHUenjMe